Incyte price target raised to $65 from $55 at Canaccord Canaccord raised its price target on Incyte citing its product pipeline outlook which includes three upcoming positive data catalysts in the first half of 2014. Shares are Buy rated.
Incyte shares poised to advance further, says Argus Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.